Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Cancer ; 92(8): 2172-80, 2001 Oct 15.
Article in English | MEDLINE | ID: mdl-11596035

ABSTRACT

BACKGROUND: Vasoactive intestinal peptide (VIP) is one of several small neuropeptides that affect cancer growth. A lipophilic VIP analog, stearyl-Nle(17)-neuroten-sin(6-11)VIP(7-28) (SNH) that inhibited lung carcinoma growth has been described previously. The experiments performed were clonogenic assays in vitro and tumor xenografts in nude mice in vivo. These studies were now extended to colon carcinoma and to combination therapy with chemotherapeutic agents. METHODS: Assays were performed with cell lines, and tumor proliferation was assessed using the (3-[4,5-dimethylthiazol-2-yl-5]-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H tetrazolium) (MTS) colorimetric assay for mitochondrial function of living cells. RESULTS: The lipophilic analog (SNH) enhanced the antiproliferative activity of diverse chemotherapeutic agents: doxorubicine (antibiotic); vinorelbine (vinca alkaloid, antimicrotubule formation); paclitaxel (antimicrotubule agent); gemcitabine (antimetabolite); irinotecan (topoisomerase I inhibitor); and cisplatin (platinum compound acting as an alkylating agent). In all cases, the antiproliferative effect of SNH and the chemotheraputic agent was at least additive and for some combinations and concentrations even synergistic. For example, 2 microM of the antagonist that produced a 15-20% growth inhibition in the nonsmall cell lung carcinoma cell line reduced the IC(50) by 2-4-fold for most of the chemotherapeutic agents tested. Higher analog concentrations were even more efficacious. Similar results were obtained with colon carcinoma cell lines. CONCLUSIONS: Chemotherapeutic treatment of advanced solid tumors, such as nonsmall cell lung carcinoma, colon carcinoma, or prostate carcinoma, achieves a response rate of between 10% and 30% with significant toxicity. Combination therapy with the lipophilic VIP analog SNH and the preferred chemotherapeutic agent may greatly enhance the response rate, and by permitting a dose reduction, should significantly reduce side effects.


Subject(s)
Antineoplastic Agents/pharmacology , Growth Inhibitors/pharmacology , Neurotensin/pharmacology , Recombinant Fusion Proteins/pharmacology , Vasoactive Intestinal Peptide/pharmacology , Animals , Carcinoma, Non-Small-Cell Lung/metabolism , Drug Synergism , Humans , Lung Neoplasms , Receptors, Vasoactive Intestinal Peptide/metabolism , Receptors, Vasoactive Intestinal Peptide, Type II , Receptors, Vasoactive Intestinal Polypeptide, Type I , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured , Tumor Stem Cell Assay , Vasoactive Intestinal Peptide/metabolism , Xenograft Model Antitumor Assays
2.
FEBS Lett ; 475(2): 71-7, 2000 Jun 16.
Article in English | MEDLINE | ID: mdl-10858491

ABSTRACT

Vasoactive intestinal peptide (VIP) is a recognized growth factor affecting many cell types. We have previously developed a series of lipophilic VIP analogues containing an N-terminal covalently attached stearyl moiety. The current studies identified stearyl-Nle(17)-VIP and stearyl-Nle(17)-neurotensin(6-11)VIP(7-28), acting at microM concentrations, as cytotoxic to human keratinocytes. The core C-terminal active VIP-derived peptide, stearyl-Lys-Lys-Tyr-Leu-NH(2) (St-KKYL-NH(2)), was identified as being responsible for the observed cytotoxicity. Cytotoxicity coincided with marked reduction in intracellular cyclic GMP and was abolished by co-treatment with the endonuclease inhibitor, aurine-tricarboxylic acid, suggesting apoptotic mechanisms. Stearyl-VIP derivatives thus offer lead compounds for future drug development against hyperproliferative skin conditions.


Subject(s)
Cell Death/drug effects , Cell Division/drug effects , Keratinocytes/cytology , Keratinocytes/pathology , Vasoactive Intestinal Peptide/chemistry , Vasoactive Intestinal Peptide/pharmacology , Apoptosis/drug effects , Aurintricarboxylic Acid/pharmacology , Cells, Cultured , Cyclic GMP/metabolism , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Humans , L-Lactate Dehydrogenase/metabolism , Microscopy, Phase-Contrast , Vasoactive Intestinal Peptide/analogs & derivatives
3.
FEBS Lett ; 475(2): 78-83, 2000 Jun 16.
Article in English | MEDLINE | ID: mdl-10858492

ABSTRACT

Vasoactive intestinal polypeptide (VIP) exhibits effects on cell proliferation. Here, VIP, as well as the related peptide, pituitary adenylate cyclase activating peptide (PACAP), promoted human keratinocyte division. Stearyl-Nle(17)-VIP (SNV) was identified as a superior mitogen for the keratinocytic cell line, HaCaT, both in potency (fM-nM concentrations) and efficacy. Reverse transcription-polymerase chain reaction detected in keratinocytes only PACAP mRNA and the relevant type 1 (VPAC(1)R) and type 2 (VPAC(2)R) receptors, while VIP and the third receptor (PAC(1)) transcripts were absent. Upon serum deprivation of HaCaT, the VPAC(1)R mRNA was apparently increased, while the VPAC(2)R transcript remained constant. Incubation of HaCaT with VIP or SNV increased nitric oxide and cGMP formation. In contrast to VIP, SNV did not augment cAMP. Thus, the paracrine VIP, and autocrine PACAP, related pathways leading to keratinocyte proliferation may involve VPAC(1)R/VPAC(2)R and nitric oxide/cGMP production.


Subject(s)
Cell Division/drug effects , Keratinocytes/cytology , Neuropeptides/pharmacology , Vasoactive Intestinal Peptide/analogs & derivatives , Vasoactive Intestinal Peptide/pharmacology , Vasodilator Agents/pharmacology , Cell Line , Cells, Cultured , Culture Media, Serum-Free/metabolism , Cyclic AMP/biosynthesis , Cyclic GMP/biosynthesis , Dose-Response Relationship, Drug , Humans , Keratinocytes/pathology , Nitric Oxide/biosynthesis , Peptides/pharmacology , Pituitary Adenylate Cyclase-Activating Polypeptide , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction
4.
Immunopharmacology ; 37(1): 43-52, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9285243

ABSTRACT

Synthesis of two chimeric peptides composed of tuftsin and thymic humoral factor-gamma 2 (THF-gamma 2) conjugates was accomplished. Our goal was the generation of novel immunomodulators. Initially, we demonstrate an IL-6 inducing activity of the phagocytic cells stimulant, tuftsin, on murine macrophages. This activity was documented only in the presence of antigen, either KLH or lysozyme. The augmentation was dose dependent, with optimal activity at a concentration of 200 and 20 nM, respectively. The chimeric peptides, either H2N-tuftsin-THF-gamma 2-OH or H2N-THF-gamma 2-tuftsin-OH, were also evaluated in the IL-6 system in the presence of the more potent antigen, KLH. The IL-6 inducing effect was maintained, although maximal activity appeared only at a concentration an order of magnitude greater than that of tuftsin. The chimeric peptides were further tested in an assay evaluating enhancement in murine bone marrow myeloid colony formation, a system in which THF-gamma 2, a T cell stimulant, has an established beneficial effect. The compounds were found to be inactive at the 25-200 ng/ml (14-112 nM) concentration range evaluated. Finally, the chimeric peptides were tested in a combined macrophages-T cells assay, i.e. antigen presentation, in which H2N-tuftsin-THF-gamma 2-OH was found to be more active than either parent peptide, thus representing a possible therapeutic agent.


Subject(s)
Adjuvants, Immunologic/pharmacology , Oligopeptides/pharmacology , Recombinant Fusion Proteins/pharmacology , Tuftsin/pharmacology , Adjuvants, Immunologic/chemical synthesis , Adjuvants, Immunologic/isolation & purification , Animals , Bone Marrow Cells/drug effects , Bone Marrow Cells/immunology , Female , Interleukin-6/biosynthesis , Interleukin-6/metabolism , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C3H , Oligopeptides/chemical synthesis , Oligopeptides/isolation & purification , Recombinant Fusion Proteins/chemical synthesis , Recombinant Fusion Proteins/isolation & purification , Tuftsin/chemical synthesis , Tuftsin/isolation & purification
5.
J Med Chem ; 39(24): 4833-43, 1996 Nov 22.
Article in English | MEDLINE | ID: mdl-8941397

ABSTRACT

Four novel 2,4-methano amino acids (MAAs, 1-aminocyclobutane-1-carboxylic acids) were synthesized. These include the basic MAA analogs of lysine (16), ornithine (5), and arginine (6) and the neutral methanovaline (22), related to proline. The above MAAs, as well as the MAA analog of homothreonine (7), were incorporated into the peptide chain of the immunomodulatory peptide tuftsin, Thr-Lys-Pro-Arg, known to enhance several biological activities mediated by phagocytic cells. The synthetic methano tuftsin analogs were assayed for their ability to stimulate interleukin-6 (IL-6) secretion by mouse peritoneal macrophages and for their stability in human serum toward enzymatic degradation. It was found that, at 2 x 10(-7) M, [MThr1]tuftsin (24) and an isomer of [MVal3]tuftsin (27a) were considerably more active than the parent peptide in augmentation of cytokine release. [MOrn2]Tuftsin (25) was equally potent. The analogs [MThr1]tuftsin (24) and [MOrn2]tuftsin (25), both pertaining to the proteolytically sensitive Thr-Lys bond of tuftsin, exhibited high resistance to enzymatic hydrolysis as compared to tuftsin. Using specific rabbit anti-tuftsin antibodies in a competitive enzyme-linked immunosorbent assay (ELISA) revealed that none of the MAA analogs can cross-react with tuftsin. It may indicate that the peptides assume global structures different than that of tuftsin.


Subject(s)
Amino Acids, Cyclic , Amino Acids , Peptides/chemical synthesis , Peptides/pharmacology , Tuftsin/analogs & derivatives , Amino Acids/chemistry , Animals , Antibodies/immunology , Antibodies/metabolism , Circular Dichroism , Endopeptidases/blood , Endopeptidases/metabolism , Enzyme-Linked Immunosorbent Assay , Humans , Interleukin-6/metabolism , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/metabolism , Magnetic Resonance Spectroscopy , Mass Spectrometry , Mice , Molecular Structure , Peptides/immunology , Peptides/metabolism , Tuftsin/analysis , Tuftsin/pharmacology
6.
Biochim Biophys Acta ; 1027(2): 199-204, 1990 Aug 24.
Article in English | MEDLINE | ID: mdl-2397231

ABSTRACT

The membrane damaging potential of dilute solutions of bile salts was evaluated by monitoring continuously the hemolysis of a small sample of red blood cells (RBC) introduced into a defined media containing the bile salts at various pH values. The strength of the hemolytic bile salt was characterized by the rate of the induced hemolysis and by the time that elapsed between the introduction of the RBC sample into the bile salt containing solution and the onset of hemolysis. The potency of the unconjugated bile acids was extremely sensitive to pH, e.g. the rate of hemolysis caused by a 7.5 mM cholate was 1.5%, 20% and 64% per min when the pH of the solution was 7.65, 7.3 and 6.85, respectively. At low pH values the membrane damaging effects of deoxycholate was clearly discerned at micromolar concentration range. The hemolytic potency of glycodeoxycholate was also enhanced significantly by lowering the pH. The taurine-conjugated cholate and deoxycholate were only slightly sensitive to variations in pH. Taurocholate at concentrations that were not hemolytic greatly enhanced the injurious potency of deoxycholate. These results imply that in acidic solutions the presence of bile acids can cause damage to cell membranes. It is suggested that the acidic environment in the proximal duodenum and acidosis developed during hypoxia in the liver are two situations in which the bile salts may constitute a pathogenic factor.


Subject(s)
Bile Acids and Salts/pharmacology , Hemolysis/drug effects , Hydrogen-Ion Concentration , Animals , Chenodeoxycholic Acid/pharmacology , Cholic Acid , Cholic Acids/pharmacology , Deoxycholic Acid/pharmacology , Erythrocytes/drug effects , Erythrocytes/physiology , Kinetics , Rats , Structure-Activity Relationship , Ursodeoxycholic Acid/pharmacology
7.
Z Parasitenkd ; 69(6): 695-701, 1983.
Article in English | MEDLINE | ID: mdl-6659650

ABSTRACT

Leishmania species grown in culture excrete a polyanionic, carbohydrate-rich factor (EF) which binds to antibodies produced in rabbits against the parent Leishmania species. EF, previously purified by physical and chemical methods, was purified by affinity chromatography on a Ricinus lectin column. The purified samples were characterised and analysed. The results show a notable proportion of galactose in EF and clarify the reasons for its polyanionic properties. Heterogenicity of EF is demonstrated and discussed.


Subject(s)
Glycoproteins/isolation & purification , Leishmania/analysis , Amino Acids/analysis , Animals , Carbohydrates/analysis , Chromatography, Affinity , Galactose/analysis , Glycoproteins/analysis , Molecular Weight , Sulfur/analysis
8.
Proc Natl Acad Sci U S A ; 73(5): 1432-6, 1976 May.
Article in English | MEDLINE | ID: mdl-1064015

ABSTRACT

Alkaline phosphatase [orthophosphoricmonoester phosphohydrolase (alkaline pH optimum), EC 3.1.3.1] purified from a Burkitt lymphoma cell line (Daudi) and Moloney-virus-induced murine leukemia (YAC) showed unique catalytic properties in substrate specificity and inhibition by cysteamine-S-phosphate. It migrated on polyacrylamide gel electrophoresis in a single activity band. Alkaline phosphatase with similar properties was found in several human lymphoblastoid cell lines, in chronic lymphatic leukemic cells, in organs of leukemic mice, and in sera of patients with certain lymphoproliferative disorders.


Subject(s)
Alkaline Phosphatase/metabolism , Leukemia, Lymphoid/enzymology , Leukemia, Myeloid, Acute/enzymology , Lymphocytes/enzymology , Alkaline Phosphatase/isolation & purification , Animals , Burkitt Lymphoma/enzymology , Cell Line , Electrophoresis, Polyacrylamide Gel , Humans , Kinetics , Leukemia, Experimental/enzymology , Mitogens , Moloney murine leukemia virus , Rats , Swine
SELECTION OF CITATIONS
SEARCH DETAIL
...